A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2014
At a glance
- Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary) ; Anthrax vaccine
- Indications Anthrax
- Focus Adverse reactions
- Sponsors PharmAthene
- 14 Sep 2008 Actual end date has been changed from Jan 2007 to Feb 2007 as reported by ClinicalTrials.gov.
- 14 Sep 2008 PharmAthene reported as trial sponsor and affliate by ClinicalTrials.gov.
- 14 Sep 2008 Primary endpoint identified as safety as reported by ClinicalTrials.gov.